AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00988715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pretargeted Radioimmunotherapy
Description: Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
Study NCT00988715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV
Study NCT00988715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00988715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study NCT00988715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant
Study NCT00988715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant
Study NCT00988715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00217438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study NCT00217438 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative study
Study NCT00988715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00988715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01942122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1442 100
Description: Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Study NCT01942122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefenamic acid
Description: Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
Study NCT01942122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1442 200
Description: Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Study NCT05150041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian connect
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
Study NCT05150041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
Study NCT05150041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPro2
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
Study NCT03607253 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: repetitive heel rise activity
Description: Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
Study NCT00741780 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT00741780 — intervention group
Intervention type: DRUG
Intervention: plerixafor
Study NCT00741780 — intervention group
Intervention type: DRUG
Intervention: granulocyte colony-stimulating factor (G-CSF)
Study NCT05615909 — intervention group
Intervention type: RADIATION
Intervention: Online MR-guided radiotherapy
Description: Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
Study NCT05615909 — intervention group
Intervention type: RADIATION
Intervention: CT-guided radiotherapy
Description: CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
Study NCT00217438 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: fluorescence in situ hybridization
Description: Correlative study
Study NCT01148186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge transfer tool
Description: knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
Study NCT00217438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Undergo transplant
Study NCT00217438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow ablation with stem cell support
Description: Undergo transplant
Study NCT02707757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
Study NCT02707757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythopoietin stimulating agent
Description: Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
Study NCT03550950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64232025 IV
Description: JNJ-64232025 will be administered as IV infusion.
Study NCT03550950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64232025 SC
Description: JNJ-64232025 will be administered as SC injection.
Study NCT03550950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as IV infusion or SC injection.
Study NCT01716156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
Study NCT00004148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-B7.1 vaccine
Study NCT04519515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergan Vollure
Description: Injection of Allergan Vollure into Atrophic Scars
Study NCT00271492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: 1 10mg capsule to be taken daily for 6 month study period.
Study NCT00271492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: 1 10mg capsule per day for the 6 month study period.
Study NCT00271492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atrasentan
Description: One 10 mg capsule per day for 6 month study period
Study NCT01490567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5 mg/day
Study NCT01490567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 5mg/d
Study NCT04165252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of vaginal, neonatal buccal and placental samples
Description: Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
Study NCT03616405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
Study NCT02528279 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Coartem
Description: Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food.
Study NCT01861535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Study NCT01861535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study NCT00918645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 41 Ca
Description: single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
Study NCT03950362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
Study NCT03950362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
Study NCT02010918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulfate /chondroitin sulfate - capsules
Description: 500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
Study NCT02010918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulfate /chondroitin sulfate - sachet
Description: 1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
Study NCT02010918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosamin DS®
Description: 500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
Study NCT03590795 — intervention group
Intervention type: OTHER
Intervention: Sleep survey
Description: The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
Study NCT04440436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T Cells
Description: IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
Study NCT01995162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy expenditure estimation
Description: Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
Study NCT02222818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conducted AF Response (CAFR)
Description: The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
Study NCT02222818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conducted AF Response Plus (CAFRPlus)
Description: The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
Study NCT01670890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMZ
Description: patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
Study NCT01670890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ plus CDDP
Description: patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
Study NCT02043132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
Study NCT02043132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
Study NCT01449188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: FDA approved drug used to treat nausea and vomiting
Study NCT01449188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: FDA approved antibiotic commonly used as a positive control in thorough QT studies
Study NCT01449188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: USP saline IV solution used as placebo for ondansetron IV.
Study NCT01528163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
Study NCT01528163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
Study NCT00764712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
Study NCT03851354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound meal acommodation test
Description: to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
Study NCT04413227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Endostatin（PEG-ENDO）
Description: PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
Study NCT04279288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm mask
Description: a cooling mask used to treat localized swelling and bleeding
Study NCT00540098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine + aerobic exercise
Description: paroxetine, 40 mg once daily + regular aerobic exercise
Study NCT00540098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine + relaxation
Description: paroxetine, 40 mg once daily + regular relaxation training
Study NCT00540098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + aerobic exercise
Description: placebo pill once daily + regular aerobic exercise
Study NCT00540098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + relaxation
Description: placebo pill once daily + regular relaxation training
Study NCT01377285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB
Description: Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan
Study NCT01377285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
Study NCT01377285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Pentoxifylline)
Description: Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
Study NCT01377285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Pentoxifylline)
Description: Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
Study NCT03119701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: Lyophilisate for solution for injection.
Study NCT03119701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilisate for solution for injection as placebo.
Study NCT01198171 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02392286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
Study NCT03488147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20 mg esomeprazole tablet
Study NCT03488147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20 mg esomeprazole tablet
Study NCT03488147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: resembling esomeprazole tablet
Study NCT03488147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: resembling esomeprazole tablet
Study NCT04537481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid extraction
Description: The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
Study NCT03839719 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group PI
Description: Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
Study NCT03839719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group OC
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
Study NCT03839719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group OC
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
Study NCT03839719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group CHX
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.